SecBot SecBot

PCSA

Processa Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001533743 Biotech & Drug Discovery
$1.75 −0.06 (−3.31%)
Oct 26 4:00 PM ET · prev $1.81
Market cap
$5.2M
Nano cap
Next earnings
Nov 4
in 9 days
1 year
−77.5%
from $7.78 · Oct 27
30 days
−4.9%
from $1.84
52-week range
$1.35–9.73
−82% from high · low Oct 8
Avg volume 20D
193.7K
Oct 9 spike 2.97M
Short interest
4.1K
≈0.1% of shares · −72.4%
Days to cover
1.0
at average volume
Insider net
+$175.4K
6 buyers · 0 sellers · since Mar 31
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH Processa Pharmaceuticals filed an S-3 registration statement to register up to 306,574,202 shares of common…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • B Apr 30 5 insiders buy $31.3K at $2.69
  • B May 15 5 insiders buy $24.7K at $2.97
  • B May 29 5 insiders buy $24.7K at $2.57
  • B Jun 15 5 insiders buy $24.7K at $2.22
  • B Jun 30 to Jul 1 2 days of insider buys: $25.9K by 5 insiders, avg $1.93
  • E Jul 29 M&A: PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VI…
  • X Sep 30 Short interest falls 72.4% to 4.1K
  • R Oct 9 Processa Pharmaceuticals filed an S-3 registration statement to regi…

Signal stack

Where each data set points today.

  • InsidersBULLISH

    6 insiders bought $175.4K at an average $2.51. No open-market sales. Price is 30% below their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • Short sellersCOVERING

    Short interest −72.4% to 4.1K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED7,794$15.0K
GEODE CAPITAL MANAGEMENT, LLCADD24,908$62.8K
UBS Group AGNEAR_EXIT2,531$6.4K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED303,304$58.2K
VANGUARD GROUP INCDOUBLED288,212$55.3K
BANK OF AMERICA CORP /DE/DOUBLED378$72.00
UBS Group AGDOUBLED64,612$13.2K
GEODE CAPITAL MANAGEMENT, LLCADD50,573$10.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Sep 2025
Recent actions
DateFirmActionRating
Sep 2, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 30, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Dec 5, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 20, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 19, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 1, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$175.4K
bought · 6 insiders
$0
sold · 0 insiders
−30.4%
vs their $2.51 cost
DateInsiderTypeValue
Aug 8, 2026
Ng George K
Chief Executive Officer
EXERCISE1,600 sh
Jul 28, 2026
GUJRATHI SHEILA
Director
AWARD70,811.877 sh
Jul 28, 2026
GUJRATHI SHEILA
Director
AWARD12,311.279 sh
Jul 26, 2026
Guy Wendy
Chief Administrative Officer
AWARD9,450 sh
Jul 26, 2026
Yorke Justin W
Director
AWARD33,500 sh
Jul 26, 2026
Pannu Geraldine
Director
AWARD33,500 sh
Jul 26, 2026
Ng George K
Chief Executive Officer
AWARD9,384 sh
Jul 26, 2026
Baluch Khoso
Director
AWARD33,500 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
4,140
shares short
-72.4%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 22, 2026 SEC
Processa Pharmaceuticals is holding a special meeting on November 30, 2026, to seek stockholder approval for a reverse…
DEF 14A — Impact 4/10
Oct 9, 2026 SEC
Processa Pharmaceuticals filed an S-3 registration statement to register up to 306,574,202 shares of common stock for…
S-3 — Impact 7/10
Aug 8, 2026 Insider
Ng George K acquired via exercise 1,600 shares
Chief Executive Officer
Aug 5, 2026 Earnings calendar
PCSA Q2 2026 Earnings Scheduled — 2026-08-05
Jul 28, 2026 Insider
GUJRATHI SHEILA was granted 70,811.877 shares
Director
Jul 28, 2026 Insider
GUJRATHI SHEILA was granted 12,311.279 shares
Director
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
7,794 shares ($15.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
PCSA Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 22, 2026
Clinical Trial
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Phase 2 · COMPLETED
Oct 22, 2026
Clinical Trial
A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Phase 2 · COMPLETED
Oct 6, 2026
Clinical Trial
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · TERMINATED
Aug 5, 2026
Earnings date
PCSA Q2 2026 Earnings Scheduled — 2026-08-05
Jul 29, 2026
M&A
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
VERO BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya…

SecBot reports

14 filings · 10 bullish · 2 bearish · 1 mixed · 1 neutral
All PCSA filing & press-release reports (14)